Serine Proteinases (3.4.21) (e.g., Trypsin, Chymotrypsin, Plasmin, Thrombin, Elastase, Kallikrein, Fibrinolysin, Streptokinease, Etc.) Patents (Class 424/94.64)
-
Publication number: 20150079063Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.Type: ApplicationFiled: May 9, 2014Publication date: March 19, 2015Applicant: OPKO Biologics Ltd.Inventors: Udi Eyal FIMA, Gili Hart
-
Publication number: 20150079072Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides.Type: ApplicationFiled: July 25, 2012Publication date: March 19, 2015Applicant: Biogen Idec Hemophilia Inc.Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
-
Publication number: 20150079068Abstract: The present application provides stabilized formulations of furin (e.g., rfurin) containing a sugar, sugar alcohol, and/or non-ionic surfactant. As compared to non-stabilized compositions, the furin formulations disclosed herein retain greater amounts of furin activity and monomeric furin content, while reducing furin aggregation when stored and/or subjected to mechanical stress. Also provided are methods for stably diluting furin (e.g., rfurin) compositions.Type: ApplicationFiled: September 25, 2014Publication date: March 19, 2015Inventors: Meinhard Hasslacher, Andrzej Citkowicz, Catherine White, Ken Franke
-
Publication number: 20150079067Abstract: This invention discloses a method to produce a pharmaceutical composition from bloods for repairing wound which don't have to extra add commercial thrombins or non-human thrombins but to manufacture the pharmaceutical composition from bloods for repairing wound directly from bloods. Therefore, the method discloses in this present invention have the effect to avoid the rejection reaction of the treated patients and to reduce the costs of production, and furthermore to decrease medical costs and the burden of patients.Type: ApplicationFiled: March 12, 2014Publication date: March 19, 2015Applicant: Taichung Hospital, Ministry of Health and WelfareInventor: Hsin-Chung TSAI
-
Publication number: 20150071909Abstract: The disclosure relates to a method of reducing the incidence of post-surgical adhesions in a subject undergoing surgery. More specifically, the method relates to reducing the incidence of post-surgical adhesions with the topically administration of variants of activated protein C with cytoprotective and antiinflammatory activity to the internal organs and tissues exposed and/or manipulated during surgery. The disclosure is also related to reducing the incidence of post-surgical adhesions with the topically administration of a variant of activated protein C with cytoprotective activity and reduced or no anticoagulant activity.Type: ApplicationFiled: September 9, 2014Publication date: March 12, 2015Inventors: Alireza R. Rezaie, Peyman Dinarvand
-
Publication number: 20150071879Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).Type: ApplicationFiled: October 17, 2014Publication date: March 12, 2015Inventor: Jan JEZEK
-
Publication number: 20150073476Abstract: The present invention relates to compositions comprising shape memory polymer (SMP) materials and uses thereof. Particularly, although not exclusively, the present invention relates to biocompatible shape memory polymer (SMP) materials and uses thereof in the medical field.Type: ApplicationFiled: October 5, 2012Publication date: March 12, 2015Inventors: Malcolm Brown, Horacio Montes de Oca Balderas, Michael Andrew Hall, Alan William Bull, David Franklin Farrar, Philip Caton-Rose, Philip David Coates, Glen Thompson, Michael Martyn, Ian MacMillan Ward, Mark James Bonner, Peter John Hine, Paul Unwin, Robin Anthony Chivers, Michael Woodhead
-
Publication number: 20150071908Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.Type: ApplicationFiled: September 12, 2013Publication date: March 12, 2015Applicant: Biosuccess Biotech Co. Ltd.Inventors: Zheng Tao Han, Hung-Fong Chen
-
Publication number: 20150071988Abstract: This invention comprises a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and a drug effective for the treatment a mammal as an aerosol and a method of treatment using the composition. The composition provides effective treatment for the longer of a period of time at least twice as long as the drug alone or up to at least one week.Type: ApplicationFiled: August 6, 2014Publication date: March 12, 2015Inventors: Kameswari S. Konduri, Sandhya N. Nandedkar, Nejat Duzgunes, Pattisapu Ram Jogi Gangadharm
-
Publication number: 20150064161Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: ApplicationFiled: June 27, 2014Publication date: March 5, 2015Inventors: Steve PAKOLA, Marc DE SMET
-
Publication number: 20150064164Abstract: The present invention relates to an agent having activity in the treatment of a tissue disruption.Type: ApplicationFiled: September 19, 2014Publication date: March 5, 2015Inventors: Jeffrey D. Edwards, Maud Louise Eijkenboom
-
Publication number: 20150064163Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.Type: ApplicationFiled: September 2, 2012Publication date: March 5, 2015Applicant: LIFENET HEALTHInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
-
Publication number: 20150064267Abstract: Fibrinolytic nanoparticles including a polymeric core having a surface that is functionalized with a cationic amphiphilic compound, and a fibrinolytic agent dispersed within the core, are described herein. The fibrinolytic nanoparticles can be used in method of dissolving a blood clot in a subject by administering to the subject a therapeutically effective amount of fibrinolytic nanoparticles.Type: ApplicationFiled: August 28, 2014Publication date: March 5, 2015Inventors: Anand Ramamurthi, Balakrishnan Sivaraman, Andrew Sylvester
-
Patent number: 8968391Abstract: Methods for ameliorating stent graft migration and endoleak using treatment site-specific cell growth promoting compositions in combination with stent grafts are disclosed. Also disclosed are application of cell growth promoting compositions such as, but not limited to, autologous platelet gel compositions directly to treatment sites during or after stent graft implantation.Type: GrantFiled: March 13, 2007Date of Patent: March 3, 2015Assignee: Medtronic Vascular, Inc.Inventors: Dennis Brooks, Jack Chu, Scott Doig, Trevor Huang, Tessy Kanayinkal
-
Patent number: 8968728Abstract: New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.Type: GrantFiled: May 11, 2007Date of Patent: March 3, 2015Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Kandaswamy Sumathy
-
Publication number: 20150050264Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.Type: ApplicationFiled: September 7, 2012Publication date: February 19, 2015Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Denis VIVIEN, Jerome PARCQ, Denis VIVIEN, Jerome PARCQ
-
Publication number: 20150044195Abstract: Disclosed are disulphide-linked complexes of a soluble Tissue Factor (sTF) variant of SEQ ID NO:3 comprising the mutation G109C and a Factor VIIa variant of SEQ ID NO. 1, comprising the mutation Q64C and a mutation at position M306 that gives rise to a zymogen-like conformation in the Factor VIIa polypeptide. Said complexes may be used for the treatment of a coagulopathy.Type: ApplicationFiled: March 15, 2013Publication date: February 12, 2015Applicant: NOVO NORDISK HEALTHCARE AGInventors: Henrik Oestergaard, Anders Laerke Nielsen, Ole Hvilsted Olsen
-
Patent number: 8951515Abstract: Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.Type: GrantFiled: March 27, 2012Date of Patent: February 10, 2015Assignee: Emory UniversityInventor: John S. Lollar
-
Publication number: 20150037314Abstract: Disclosed is a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. Further disclosed are methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes.Type: ApplicationFiled: October 17, 2014Publication date: February 5, 2015Inventor: Kristian Larsen
-
Publication number: 20150031544Abstract: The present invention relates to formulations and methods for stabilizing and protecting of biologic materials during harsh storing and use conditions, wherein the formulations relate to embedded bioactive materials and biologics, including live bacteria, in a protective glassy matrix.Type: ApplicationFiled: August 11, 2014Publication date: January 29, 2015Applicant: Advanced Bionutrition CorporationInventors: Moti HAREL, Roger Drewes, January Scarbrough
-
Patent number: 8940335Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a dry granular preparation of a biocompatible polymer suitable for use in hemostasis, b) coating the granules in said dry granular preparation with a preparation of a coagulation inducing agent, thereby obtaining coagulation inducing agent coated polymer granules, c) filling said coagulation inducing agent coated polymer granules into a final container, d) finishing the final container to a storable pharmaceutical device containing said coagulation inducing agent coated polymer granules as a dry and stable hemostatic composition.Type: GrantFiled: June 1, 2011Date of Patent: January 27, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventor: Andreas Goessl
-
Patent number: 8940699Abstract: The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents.Type: GrantFiled: June 10, 2010Date of Patent: January 27, 2015Assignee: NoNO Inc.Inventors: Michael Tymianski, Jonathan David Garman
-
Patent number: 8940297Abstract: One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition.Type: GrantFiled: December 20, 2011Date of Patent: January 27, 2015Assignee: Saint Louis UniversityInventors: Enrico Di Cera, Andras Gruber, Prafull Gandhi, Leslie Pelc, Nicola Pozzi, David Collier Wood
-
Publication number: 20150023947Abstract: A virally safe, thrombin-free factor-XIa concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation.Type: ApplicationFiled: July 21, 2014Publication date: January 22, 2015Inventor: Johann EIBL
-
Publication number: 20150017225Abstract: The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue.Type: ApplicationFiled: July 9, 2013Publication date: January 15, 2015Inventors: Randolph W. Hubbell, James Eckhardt, Jerome Riebman, Yufu Li, Michael Elser
-
Publication number: 20150010530Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.Type: ApplicationFiled: July 9, 2014Publication date: January 8, 2015Inventor: Gary L. Nelsestuen
-
Publication number: 20150010531Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.Type: ApplicationFiled: July 31, 2014Publication date: January 8, 2015Applicant: ANNEXIN PHARMACEUTICALS ABInventors: Johan FROSTEGÅRD, Knut PETTERSSON
-
Publication number: 20150004153Abstract: A pest-combating composition including sodium lauryl sulfate and one or more of C6-12 fatty acids, preferably lauric and/or capric and/or caprylic acid, soy methyl ester, and 2-undecanone, and methods of combating pests utilizing same, are disclosed. The compositions can include a carrier oil such as silicon oil, soy methyl ester, or a vegetable oil, and can be in the form of an emulsion. The composition may be constituted as a spray composition, an aerosol, a lotion, a paste, or another compositional form. Pests that may be usefully combated with such composition include flying insects, including flies, mosquitoes, and wasps, ants, including arthropods such as fire ants, ticks, fleas, cockroaches, silver fish, thrips, gnats, aphids, Japanese beetles, and agricultural and horticultural arthropods and insects including beetles (potato and bean), flea beetles, fleahoppers, squash bugs, slugs, leaf hoppers, harlequin bugs, milk weed bugs, spiders, mites, lice, rodents, and deer.Type: ApplicationFiled: September 15, 2014Publication date: January 1, 2015Applicant: HOMS, LLCInventor: Allen Jones
-
Patent number: 8920794Abstract: The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of a plasmin or active derivative thereof in the form of topical eye drops alone, by anterior chamber injection alone, or by any combination of these.Type: GrantFiled: August 16, 2013Date of Patent: December 30, 2014Assignee: ThromboGenics NVInventors: Jean-Marie Stassen, Ingeborg Stalmans
-
Publication number: 20140377247Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: ApplicationFiled: February 7, 2014Publication date: December 25, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Bing-Yan ZHU, Penglie ZHANG, Lingyan WANG, Wenrong HUANG, Erick A. GOLDMAN, Wenhao LI, Jingmei ZUCKETT, Yonghong SONG, Robert M. SCARBOROUGH
-
Patent number: 8916148Abstract: A method is disclosed for using tenecteplase to restore function in dysfunctional hemodialysis catheters, which have a blood flow rate of less than 300 mL/minute. Kits are also provided with instructions to direct the user to administer tenecteplase in a total dose of about 3 to 4 mg locally into all catheter lumens and allow the tenecteplase to dwell in the catheter for from about one hour to about 72 hours.Type: GrantFiled: October 30, 2007Date of Patent: December 23, 2014Assignee: Genentech, Inc.Inventor: Martha E. Blaney
-
Patent number: 8916149Abstract: Provided are polypeptides comprising a variant activated protein C comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Also provided are nucleic acids encoding the polypeptides, and cells, compositions and kits containing the polypeptides and nucleic acids. Also provided are methods of treating sepsis in a subject comprising administering to the subject one or more of the provided polypeptides or nucleic acids. Methods of screening for polypeptides with enhanced activated protein C and for an agent for treatment of sepsis are provided. Finally, provided is a method of treating sepsis in a subject comprising administering to the subject a pharmaceutical composition comprising one or more RGD-containing peptides.Type: GrantFiled: November 3, 2009Date of Patent: December 23, 2014Assignee: University of RochesterInventor: Minsoo Kim
-
Patent number: 8916190Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.Type: GrantFiled: June 18, 2013Date of Patent: December 23, 2014Assignee: St. Teresa Medical Inc.Inventors: Curtis E. Olson, Philip A. Messina
-
Publication number: 20140369994Abstract: Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: William N. Drohan, Michael J. Griffith
-
Publication number: 20140369993Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.Type: ApplicationFiled: January 22, 2013Publication date: December 18, 2014Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer, Clive Wilson, Anthony Pettigrew, Annette Hüttig
-
Publication number: 20140369991Abstract: The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.Type: ApplicationFiled: July 6, 2012Publication date: December 18, 2014Applicant: Profibrix BVInventors: Eliane Schutte, Linda Zuckerman, Richard Senderoff, Glen Martyn
-
Publication number: 20140369992Abstract: The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins.Type: ApplicationFiled: June 12, 2014Publication date: December 18, 2014Inventor: Ed Pryzdial
-
Publication number: 20140369995Abstract: The present invention provides compositions and methods for treating stroke patients using TCM and a Western medicament used for the treatment of stroke patients.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: David Picard, Shi Xue Min, Michael Lazdunski
-
Publication number: 20140363419Abstract: Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.Type: ApplicationFiled: July 25, 2014Publication date: December 11, 2014Applicant: BAYER HEALTHCARE LLCInventors: Maxine BAUZON, Terry Hermiston
-
Patent number: 8906366Abstract: Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, compositions comprising Factor X and Factor Xa, inactivated Factor X and inactivated Factor Xa and methods of medical treatment using Factor X, Factor Xa, activated Factor X and inactivated Factor Xa are disclosed. The preparation methods comprise a chromatography step using an immobilised metal ion affinity chromatography substrate.Type: GrantFiled: May 29, 2008Date of Patent: December 9, 2014Assignee: NHS Blood and TransplantInventors: Joanne Lloyd, Peter Feldman
-
Patent number: 8906662Abstract: Provided are compositions and methods for treating inflammation due to an immune response. Non-limiting example compositions include class-2 SPATE proteins that are capable of cleaving proteins involved in an inflammatory immune response in a patient. Example compositions include at least one mucin-cleaving class-2 SPATE protein. Further example compositions include protein involved in intestinal colonization (Pic). Non-limiting example methods include methods of decreasing inflammation in a patient having inflammation and methods of perturbing immune response in a patient having a disease or condition in which an active immune response is attributable to a cause of the disease or condition, by administering to the patient a composition including at least one class-2 SPATE protein capable of cleaving proteins involved in an inflammatory immune response.Type: GrantFiled: December 22, 2010Date of Patent: December 9, 2014Assignee: University of Maryland, BaltimoreInventors: James Nataro, Fernando Ruiz-Perez
-
Publication number: 20140356346Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.Type: ApplicationFiled: May 15, 2014Publication date: December 4, 2014Applicant: CSL Behring GmbHInventors: Thomas WEIMER, Stefan SCHULTE, Ulrich KRONTHALER, Wiegand LANG, Uwe LIEBING, Wilfried WORMSBÄCHER
-
Publication number: 20140356347Abstract: The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer.Type: ApplicationFiled: September 21, 2012Publication date: December 4, 2014Inventors: Stefan Barth, Sonja Schiffer, Grit Hehmann-Titt
-
Publication number: 20140356344Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: August 20, 2014Publication date: December 4, 2014Applicant: BioAtla LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20140356378Abstract: Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicant: GENERA ISTRAZIVANJA d.o.oInventors: Slobodan VUKICEVIC, Lovorka GRGUREVIC, Boris MACEK
-
Publication number: 20140346073Abstract: A wound dressing includes a backing material, and thrombin, applied to the backing material. Preferably, the backing material includes biodegradable polyester, such as electrospun polycaprolactone. The thrombin preferably includes salmon thrombin adsorbed onto the backing material. A process of fabricating a wound dressing includes applying thrombin to the backing material. Preferably, the thrombin is prepared from the plasma of a salmonid. The thrombin is applied to the backing material by adsorbing the thrombin onto the backing material, preferably after applying a detergent solution to the backing material. The dressing can be lyophilized and vacuum-sealed within an air-tight wrapping.Type: ApplicationFiled: July 8, 2014Publication date: November 27, 2014Applicant: SEA RUN HOLDINGS, INC.Inventors: Evelyn S. Sawyer, Paul A. Janmey
-
Publication number: 20140348810Abstract: An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and optionally one or more bioactive agent. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. The method of using in situ gel-forming composition for various applications is also disclosed.Type: ApplicationFiled: August 8, 2014Publication date: November 27, 2014Applicant: POLY-MED, INC.Inventor: Shalaby W. Shalaby
-
Patent number: 8895047Abstract: Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.Type: GrantFiled: May 21, 2008Date of Patent: November 25, 2014Assignee: Arrow International, Inc.Inventors: Nisha Gupta, Joel Rosenblatt, Daniel J. Spangler
-
Publication number: 20140341881Abstract: This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor.Type: ApplicationFiled: July 30, 2014Publication date: November 20, 2014Inventors: David Deperthes, Christoph Kundig, Alain Hovnanian, Celine Deraison
-
Publication number: 20140341879Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof wherein the peptide is D-Arg-26-Dmt-Lys-Phe-NH2 (SS-31).Type: ApplicationFiled: January 7, 2014Publication date: November 20, 2014Applicant: Stealth Peptides International, Inc.Inventors: Kenneth Borow, D. Travis Wilson